Updated breast cancer guidelines reinforce genomic testing

Genomic Health announced that the 15th St. Gallen International Breast Cancer Conference Expert Panel endorsed the use of genomic tests in early-stage breast cancer and recognised the Oncotype DX Breast Recurrence Score test for its prognostic ability as well as its value in guiding treatment decisions on adjuvant chemotherapy for patients with early-stage, endocrine sensitive, invasive breast cancer.

Genomic testing is the new go-to method for early detection of breast cancer.
Genomic testing is the new go-to method for early detection of breast cancer.
Source: shutterstock/hywards

In particular, Oncotype DX was the only test supported by a majority of panelists (58.6 percent) for its value in providing information that can help physicians “decide to omit chemotherapy” in patients with node positive disease (up to three nodes). The guidelines, which are reviewed bi-annually, have been recently published online in the Advance Access section of Annals of Oncology and will appear in a future print issue.  

“We are pleased that this expert panel once again recognized the value of the Oncotype DX test. An extensive body of clinical evidence highlights the unique ability of our test to identify both patients who can be spared chemotherapy and – importantly - those who will clearly benefit from it, while providing a positive impact on healthcare systems,” said Calvin Chao, Vice President of Global Medical Affairs at Genomic Health. “In addition to these updated guidelines, it is encouraging to see recently published data reinforcing that there is a spectrum of biology in breast cancer and growing evidence from all research groups on the importance of more precise estimates of risk and chemotherapy benefit as provided by the Oncotype DX individualized Recurrence Score result.”

The Oncotype DX Breast Recurrence Score test is incorporated in all major international guidelines, including NICE, St. Gallen International Breast Cancer Expert Panel, ESMO, ASCO and NCCN. The test was also included in the 8th edition of the American Joint Committee on Cancer (AJCC) criteria for breast cancer staging, which will be effective in January 2018. This is particularly significant since AJCC has, for the first time, added molecular markers to staging criteria and identified Oncotype DX as the only gene test that can be used to determine formal staging of breast cancer patients along with hormonal status (ER, PR), and HER2 status.

Breast cancer is the most common cancer in European women and affects many of them during their years dedicated to working and raising a family. While chemotherapy is routinely offered, research shows that less than 10 percent of patients with early-stage breast cancer actually benefit from it.
The Oncotype DX test is designed to facilitate personalized clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems. This is supported by substantial real-world evidence showing that the test can reduce the number of women undergoing unnecessary chemotherapy by up to 60 percent.


Source: Genomic Health


Read all latest stories

Related articles


News • MammaPrint test

New test to save breast cancer patients from over-treatment

A new test may help to identify breast cancer patients with the lowest risk of death, therefore helping them to avoid unnecessarily aggressive treatment.


News • cfDNA to assess tumours

Recurrent breast cancer: liquid biopsy improves detection, monitoring

Liquid biopsy performed on serum samples taken from breast cancer patients can provide increasingly accurate information on progression and enable earlier detection of recurrence.


News • NGS-based diagnostics

Collaboration on early detection of recurrent breast cancer

Together with Imperial College London (‘Imperial’), molecular diagnostics company DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next…

Related products

Subscribe to Newsletter